Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Investor Update - October 19, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Bain-backed startup strikes $500M deal with Eli Lilly
A month after detailing its strategic shift toward autoimmune diseases and cancer, Nimbus Therapeutics has captured the interest of a major pharmaceutical player. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - October 11, 2022 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
Drug Shows Promise Against Autoimmune Disease Scleroderma
MONDAY, Oct. 10, 2022 -- Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition.
The disease, a subset of scleroderma, hardens the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2022 Category: General Medicine Source Type: news
Tofacitinib Shows Promise Against Autoimmune Disease Scleroderma
MONDAY, Oct. 10, 2022 -- Researchers report early success with using an existing rheumatoid arthritis (RA) drug to treat systemic sclerosis, a rare but potentially devastating autoimmune condition.
The disease, a subset of scleroderma, hardens the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 10, 2022 Category: General Medicine Source Type: news
Unlocking the secrets of Graves ’ disease
Manglik, Cheng, and colleagues break decades-long impasse in understanding a common autoimmune disorder. (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - October 6, 2022 Category: Universities & Medical Training Source Type: news
Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
New positive data fromEvrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapyprogramme forDuchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials ingeneralised myasthenia gravis (gMG), a rare chronic autoimmune disease, andfacioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorderBasel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading n...
Source: Roche Media News - October 5, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new data from its expanding neuromuscular disease portfolio at World Muscle Society 2022
New positive data fromEvrysdi, a treatment for spinal muscular atrophy (SMA), a progressive neuromuscular disease that can be fatalData from the gene therapyprogramme forDuchenne muscular dystrophy (DMD), a progressive disease that leads to premature death, reinforce confidence in the most advanced Phase 3 study currently underwayStudy designs of two new trials ingeneralised myasthenia gravis (gMG), a rare chronic autoimmune disease, andfacioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorderBasel, 05 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its industry-leading n...
Source: Roche Investor Update - October 5, 2022 Category: Pharmaceuticals Source Type: news
Causal Effect of Autoimmune Liver Diseases on Cancer Causal Effect of Autoimmune Liver Diseases on Cancer
Do patients with autoimmune liver diseases have an increased risk of cancer and cancer-related death?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Cell-Killing Cancer Therapy Treats Lupus Successfully Cell-Killing Cancer Therapy Treats Lupus Successfully
' Our data reveal unexpected insights for a role of CAR T cells in nonmalignant diseases that could provide new opportunities for the treatment of autoimmune disease, ' the study authors write.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 22, 2022 Category: Cancer & Oncology Tags: Rheumatology News Source Type: news
Study suggests Long Covid could leave you at risk of autoimmune disease one year on
It's been clear since the emergence of Covid that the virus compromises immune functions by attacking white cells that fight infection, but the long-term consequences of this have remained poorly understood. (Source: Daily Express - Health)
Source: Daily Express - Health - September 22, 2022 Category: Consumer Health News Source Type: news
Incident Cardiovascular Disease Risk Up With Autoimmune Disease
FRIDAY, Sept. 16, 2022 -- Individuals with autoimmune disease have an increased risk for developing incident cardiovascular disease, according to a study published online Aug. 27 in The Lancet to coincide with the European Society of Cardiology... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 16, 2022 Category: Pharmaceuticals Source Type: news
Cell-killing cancer therapy shows promise for a devastating autoimmune disorder
Opening a new frontier in fighting autoimmune disease, researchers have successfully treated five lupus patients with a novel cell therapy that turns run-of-the-mill immune cells into specialized hunters of rogue cells helping fuel illness. The patients treated with the new therapy all saw their severe symptoms, including kidney and other organ dysfunction, largely disappear.
The results “are phenomenal,” says Betty Diamond, an immunologist and rheumatologist at the Feinstein Institutes for Medical Research who cares for lupus patients and was not involved in the work. Despite her excitement, she cautions that th...
Source: ScienceNOW - September 15, 2022 Category: Science Source Type: news
Scientists hail autoimmune disease therapy breakthrough
Study finds CAR T-cell treatment sends lupus into remission, raising hopes it could be used to treat diseases such multiple sclerosisFive people with severe autoimmune disease have become the first in the world to receive a groundbreaking therapy that uses genetically altered cells to drive the illness into remission.The four women and one man, aged 18 to 24, received transfusions of modified immune cells to treat severe lupus, an autoimmune disease that can cause life-threatening damage to the heart, lungs, brain and kidneys.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - September 15, 2022 Category: Science Authors: Ian Sample Science editor Tags: Science Health Genetics Multiple sclerosis Source Type: news
